Application of novel thrombosis markers in neurosurgical critical care

doi:10.3877/cma.j.issn.2095-9141.2025.04.009

Abstract

Abstract:

Imbalance between coagulation and fibrinolysis is a key inducer of complications in neurosurgical critical care (such as traumatic brain injury, intracranial hemorrhage, and perioperative period of brain tumors). Novel thrombosis markers (thrombin-antithrombin complex, plasmin-α2-plasmin inhibitor complex, tissue-type plasminogen activator-inhibitor complex, and thrombomodulin) can monitor coagulation activation, fibrinolytic activity, and endothelial injury in an earlier and more sensitive manner. They provide a basis for diagnosis and treatment adjustment (e.g., anticoagulant or antifibrinolytic regimens) and also help predict risks such as thrombosis and rebleeding. The purpose of this review is to clarify the value of these novel markers in the precise diagnosis and treatment of neurosurgical critical care, analyze current application limitations, and propose future research directions. It aims to provide theoretical references for optimizing clinical patient management, reducing secondary brain injury, and improving prognosis, as well as offer directional references for subsequent research.

Key words: Neurosurgical critical care, Novel thrombosis markers, Coagulation and fibrinolytic systems

Ziqian Zhang, Na Wang, Hao Zhao. Application of novel thrombosis markers in neurosurgical critical care[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2025, 11(04): 264-269.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2025.04.009

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2025/V11/I04/264

References 48

[1]	Tokarev AA, Butylin AA, Ataullakhanov FI. Platelet adhesion from shear blood flow is controlled by near-wall rebounding collisions with erythrocytes[J]. Biophys J, 2011, 100(4): 799-808. DOI: 10.1016/j.bpj.2010.12.3740.
[2]	Chang R, Cardenas JC, Wade CE, et al. Advances in the understanding of trauma-induced coagulopathy[J]. Blood, 2016, 128(8): 1043-1049. DOI: 10.1182/blood-2016-01-636423.
[3]	Gavins FN, Russell J, Senchenkova EL, et al. Mechanisms of enhanced thrombus formation in cerebral microvessels of mice expressing hemoglobin-s[J]. Blood, 2011, 117(15): 4125-4133. DOI: 10.1182/blood-2010-08-301366.
[4]	Fan X, Yu Z, Liu J, et al. Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy[J]. Stroke, 2010, 41(10 Suppl): S54-S58. DOI: 10.1161/strokeaha.110.596106.
[5]	Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation[J]. Blood, 2019, 133(6): 511-520. DOI: 10.1182/blood-2018-07-818211.
[6]	袁强，虞剑，陈建，等.颅脑创伤急性期凝血功能障碍诊治专家共识(2024版)[J].中华创伤杂志, 2024, 40(4): 310-322. DOI: 10.3760/cma.j.cn501098-20231107-00293.
[7]	Todd J, Bharadwaj VN, Nellenbach K, et al. Platelet-like particles reduce coagulopathy-related and neuroinflammatory pathologies post-experimental traumatic brain injury[J]. J Biomed Mater Res B Appl Biomater, 2021, 109(12): 2268-2278. DOI: 10.1002/jbm.b.34888.
[8]	Rimaitis M, Cechanovičiūtė V, Bilskienė D, et al. Dynamic changes of hemostasis in patients with traumatic brain injury undergoing craniotomy: association with in-hospital mortality[J]. Neurocrit Care, 2023, 38(3): 714-725. DOI: 10.1007/s12028-022-01639-4.
[9]	Dean T, Mendiola AS, Yan Z, et al. Fibrin promotes oxidative stress and neuronal loss in traumatic brain injury via innate immune activation[J]. J Neuroinflammation, 2024, 21(1): 94. DOI: 10.1186/s12974-024-03092-w.
[10]	Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors[J]. Semin Thromb Hemost, 2014, 40(3): 325-331. DOI: 10.1055/s-0034-1370791.
[11]	Magnus N, D'Asti E, Garnier D, et al. Brain neoplasms and coagulation[J]. Semin Thromb Hemost, 2013, 39(8): 881-895. DOI: 10.1055/s-0033-1357483.
[12]	Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2015, 46(7): 2032-2060. DOI: 10.1161/str.0000000000000069.
[13]	Gorzelak-Pabiś P, Pawlos A, Broncel M, et al. Expression of anti and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: a comparison of rivaroxaban and dabigatran[J]. Clin Exp Pharmacol Physiol, 2022, 49(8): 805-812. DOI: 10.1111/1440-1681.13668.
[14]	Yang K, Zeng L, Ge A, et al. A systematic review of the research progress of non-coding RNA in neuroinflammation and immune regulation in cerebral infarction/ischemia-reperfusion injury[J]. Front Immunol, 2022, 13: 930171. DOI: 10.3389/fimmu.2022.930171.
[15]	Dziedzic T. Systemic inflammation as a therapeutic target in acute ischemic stroke[J]. Expert Rev Neurother, 2015, 15(5): 523-531. DOI: 10.1586/14737175.2015.1035712.
[16]	Maegele M, Schöchl H, Menovsky T, et al. Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management[J]. Lancet Neurol, 2017, 16(8): 630-647. DOI: 10.1016/s1474-4422(17)30197-7.
[17]	Thiebaut AM, Gauberti M, Ali C, et al. The role of plasminogen activators in stroke treatment: fibrinolysis and beyond[J]. Lancet Neurol, 2018, 17(12): 1121-1132. DOI: 10.1016/s1474-4422(18)30323-5.
[18]	Jin R, Xiao AY, Li J, et al. PI3Kγ (Phosphoinositide 3-Kinase-γ) inhibition attenuates tissue-type plasminogen activator-induced brain hemorrhage and improves microvascular patency after embolic stroke[J]. Hypertension, 2019, 73(1): 206-216. DOI: 10.1161/hypertensionaha.118.12001.
[19]	徐文心，封启明.严重创伤患者纤溶异常的研究进展[J].中国急救医学, 2019, 39(2): 178-181. DOI: 10.3969/j.issn.1002-1949.2019.02.021.
[20]	颜小荣，康德智.脑挫裂伤后脑内血肿进展性扩大的危险因素[J].中华神经创伤外科电子杂志, 2017, 3(1): 51-53. DOI: 10.3877/cma.j.issn.2095-9141.2017.01.013.
[21]	Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage[J]. Lancet, 2009, 373(9675): 1632-1644. DOI: 10.1016/s0140-6736(09)60371-8.
[22]	del Zoppo GJ. Thrombolytic therapy in the treatment of stroke[J]. Drugs, 1997, 54 Suppl 3: 90-99. DOI: 10.2165/00003495-199700543-00013.
[23]	Ariëns RA, de Lange M, Snieder H, et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state[J]. Lancet, 2002, 359(9307): 667-671. DOI: 10.1016/s0140-6736(02)07813-3.
[24]	Singh S, Kumar P, Padwad YS, et al. Targeting fibrinolytic inhibition for venous thromboembolism treatment: overview of an emerging therapeutic approach[J]. Circulation, 2024, 150(11): 884-898. DOI: 10.1161/circulationaha.124.069728.
[25]	Abdul S, Leebeek FW, Rijken DC, et al. Natural heterogeneity of α2-antiplasmin: functional and clinical consequences[J]. Blood, 2016, 127(5): 538-545. DOI: 10.1182/blood-2015-09-670117.
[26]	Nekludov M, Antovic J, Bredbacka S, et al. Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers[J]. J Neurotrauma, 2007, 24(1): 174-180. DOI: 10.1089/neu.2006.0173.
[27]	Rausa E, Kelly ME, Asti E, et al. Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: systematic review and meta-analysis of randomized clinical trials[J]. Surgery, 2018, 164(6): 1234-1240. DOI: 10.1016/j.surg.2018.05.028.
[28]	Lee SY, Niikura T, Iwakura T, et al. Thrombin-antithrombin III complex tests[J]. J Orthop Surg (Hong Kong), 2017, 25(1): 170840616684501. DOI: 10.1177/0170840616684501.
[29]	Liu Y, Ma J, Shi Q, et al. Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment[J]. Health Sci Rep, 2021, 4(1): e218. DOI: 10.1002/hsr2.218.
[30]	Zunker P, Schick A, Padró T, et al. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology[J]. Neurol Res, 1999, 21(8): 727-732. DOI: 10.1080/01616412.1999.11741005.
[31]	Winter MP, Kleber ME, Koller L, et al. Prognostic significance of tPA/PAI-1 complex in patients with heart failure and preserved ejection fraction[J]. Thromb Haemost, 2017, 117(3): 471-478. DOI: 10.1160/th16-08-0600.
[32]	Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta[J]. J Cell Biol, 1985, 101(2): 363-371. DOI: 10.1083/jcb.101.2.363.
[33]	Zhang X, Hu Y, Hong M, et al. Plasma thrombomodulin, fibrinogen, and activity of tissue factor as risk factors for acute cerebral infarction[J]. Am J Clin Pathol, 2007, 128(2): 287-292. DOI: 10.1309/hb6ab1yr4dqut5au.
[34]	Koyama K, Madoiwa S, Nunomiya S, et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study[J]. Crit Care, 2014, 18(1): R13. DOI: 10.1186/cc13190.
[35]	Lundbech M, Krag AE, Christensen TD, et al. Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients[J]. Thromb Res, 2020, 186: 80-85. DOI: 10.1016/j.thromres.2019.12.018.
[36]	Pottier P, Fouassier M, Hardouin JB, et al. D-dimers, thrombin-antithrombin complexes, and risk factors for thromboembolism in hospitalized patient[J]. Clin Appl Thromb Hemost, 2009, 15(6): 666-675. DOI: 10.1177/1076029608321436.
[37]	Yamada S, Asakura H. Therapeutic strategies for disseminated intravascular coagulation associated with aortic aneurysm[J]. Int J Mol Sci, 2022, 23(3): 1296. DOI: 10.3390/ijms23031296.
[38]	Hilmi IA, Planinsic RM. Live liver donors: are they at a higher risk for post-operative thrombotic complications?[J]. World J Transplant, 2012, 2(1): 1-4. DOI: 10.5500/wjt.v2.i1.1.
[39]	Guo X, Tao H, Li D, et al. The α2-plasmin inhibitor-plasmin complex is a potential biomarker of venous thromboembolism in orthopedic trauma patients[J]. Clin Lab, 2021, 67(4): 856. DOI: 10.7754/Clin.Lab.2020.200856.
[40]	Nielsen VG, Matika RW, Ley ML, et al. Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer[J]. Blood Coagul Fibrinolysis, 2014, 25(3): 248-253. DOI: 10.1097/mbc.0000000000000040.
[41]	Yagi K, Tao Y, Hara K, et al. Increased plasma plasmin-α2-plasmin inhibitor complex levels correlate with postoperative rebleeding after endoscopic surgery for spontaneous intracerebral hemorrhage[J]. Acta Neurochir (Wien), 2020, 162(12): 3129-3136. DOI: 10.1007/s00701-019-04154-2.
[42]	Johansson L, Jansson JH, Boman K, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke[J]. Stroke, 2000, 31(1): 26-32. DOI: 10.1161/01.str.31.1.26.
[43]	Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease[J]. Biochem Soc Trans, 2011, 39(4): 898-901. DOI: 10.1042/bst0390898.
[44]	Hino H, Akiyama H, Iseki E, et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in rat and human brain tissues[J]. Neurosci Lett, 2001, 297(2): 105-108. DOI: 10.1016/s0304-3940(00)01679-7.
[45]	Pletsch-Borba L, Grafetstätter M, Hüsing A, et al. Vascular injury biomarkers and stroke risk: a population-based study[J]. Neurology, 2020, 94(22): e2337-e2345. DOI: 10.1212/wnl.0000000000009391.
[46]	Olivot JM, Labreuche J, Aiach M, et al. Soluble thrombomodulin and brain infarction: case-control and prospective study[J]. Stroke, 2004, 35(8): 1946-1951. DOI: 10.1161/01.STR.0000133340.37712.9b.
[47]	Bai H, Shen L, Zhang H, et al. Clinical value of TAT, PIC and t-PAIC as predictive markers for severe sepsis in pediatric patients[J]. Front Pediatr, 2024, 121336583. DOI: 10.3389/fped.2024.1336583.
[48]	Abdelmaguid A, Roberts LN, Tugores L, et al. Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease[J]. J Thromb Haemost, 2022, 20(4): 845-856. DOI: 10.1111/jth.15653.

Please choose a citation manager

Content to export